Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

116 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
2-year clinical outcomes after implantation of sirolimus-eluting, paclitaxel-eluting, and bare-metal coronary stents: results from the WDHR (Western Denmark Heart Registry).
Kaltoft A, Jensen LO, Maeng M, Tilsted HH, Thayssen P, Bøttcher M, Lassen JF, Krusell LR, Rasmussen K, Hansen KN, Pedersen L, Johnsen SP, Sørensen HT, Thuesen L. Kaltoft A, et al. Among authors: tilsted hh. J Am Coll Cardiol. 2009 Feb 24;53(8):658-64. doi: 10.1016/j.jacc.2008.09.058. J Am Coll Cardiol. 2009. PMID: 19232897 Free article.
Clinical outcome after primary percutaneous coronary intervention with drug-eluting and bare metal stents in patients with ST-segment elevation myocardial infarction.
Jensen LO, Maeng M, Thayssen P, Kaltoft A, Tilsted HH, Bøttcher M, Lassen JF, Hansen KN, Krusell LR, Rasmussen K, Pedersen KE, Pedersen L, Paaske Johnsen S, Sørensen HT, Thuesen L. Jensen LO, et al. Among authors: tilsted hh. Circ Cardiovasc Interv. 2008 Dec;1(3):176-84. doi: 10.1161/CIRCINTERVENTIONS.108.794578. Circ Cardiovasc Interv. 2008. PMID: 20031676
Efficacy and safety of zotarolimus-eluting and sirolimus-eluting coronary stents in routine clinical care (SORT OUT III): a randomised controlled superiority trial.
Rasmussen K, Maeng M, Kaltoft A, Thayssen P, Kelbaek H, Tilsted HH, Abildgaard U, Christiansen EH, Engstrøm T, Krusell LR, Ravkilde J, Hansen PR, Hansen KN, Abildstrøm SZ, Aarøe J, Jensen JS, Kristensen SD, Bøtker HE, Madsen M, Johnsen SP, Jensen LO, Sørensen HT, Thuesen L, Lassen JF; SORT OUT III study group. Rasmussen K, et al. Among authors: tilsted hh. Lancet. 2010 Mar 27;375(9720):1090-9. doi: 10.1016/S0140-6736(10)60208-5. Epub 2010 Mar 16. Lancet. 2010. PMID: 20231034 Clinical Trial.
Rationale and design of a randomized clinical comparison of everolimus-eluting (Xience v/Promus) and sirolimus-eluting (cypher select+) coronary stents in unselected patients with coronary heart disease.
Jensen LO, Thayssen P, Tilsted HH, Ravkilde J, Junker A, Hansen HS, Hansen KN, Pedersen KE, Sørensen HT, Thuesen L, Lassen JF; Scandinavian Organization for Randomized Trials with Clinical Outcome SORT OUT IV investigators. Jensen LO, et al. Among authors: tilsted hh. Cardiology. 2010;116(2):73-8. doi: 10.1159/000315136. Epub 2010 Jun 3. Cardiology. 2010. PMID: 20523042 Clinical Trial.
Late lumen loss and intima hyperplasia after sirolimus-eluting and zotarolimus-eluting stent implantation in diabetic patients: the diabetes and drug-eluting stent (DiabeDES III) angiography and intravascular ultrasound trial.
Jensen LO, Maeng M, Thayssen P, Villadsen A, Krusell L, Botker HE, Pedersen KE, Aaroe J, Christiansen EH, Vesterlund T, Hansen KN, Ravkilde J, Tilsted HH, Lassen JF, Thuesen L. Jensen LO, et al. Among authors: tilsted hh. EuroIntervention. 2011 Jul;7(3):323-31. doi: 10.4244/EIJV7I3A56. EuroIntervention. 2011. PMID: 21729834 Free article. Clinical Trial.
116 results